Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00256399 · ClinicalTrials.gov registry record · NA

Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

A NA study of Erectile Dysfunction and BPH, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT00256399 is a NA study of Erectile Dysfunction and BPH that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 6 participants, below the 231-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00256399, a NA study of Erectile Dysfunction and BPH, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.

Conditions Studied

Interventions

  • DRUG Alfuzosin 10 mg

Study Locations (1)

Ohio

  • University Hospitals of Cleveland - Cleveland

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2005-11
Est. Completion 2007-05-08
Phase NA

What the Registry Record Tells You About NCT00256399

The ClinicalTrials.gov registry entry for NCT00256399 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (97% lower). The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Erectile Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Alfuzosin 10 mg is the first listed.

NCT00256399 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00256399 about?

NCT00256399 is a clinical study titled "Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)". Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.

What is the current status of trial NCT00256399?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2005-11. Estimated completion is 2007-05-08.

What conditions does trial NCT00256399 study?

This clinical trial studies the following conditions: Erectile Dysfunction, BPH.

What interventions are being tested in trial NCT00256399?

The interventions under investigation include: Alfuzosin 10 mg (DRUG).

Who is sponsoring clinical trial NCT00256399?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00256399 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Erectile Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.